MEMORANDUM FOR SGVT
ATTN: CAPT NICHOLAS SCALZITTI

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled **Assessing How Hospital Readmissions are Affected by Obstructive Sleep Apnea Severity and Therapy Compliance** presented at/published to **Sleep 2017, Boston, MA, 3-7 June 2017** in accordance with MDWI 41-108, has been approved and assigned local file #17156.

2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.

3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are a 59 MDW staff member, we can forward your request for funds to the designated Wing POC at the Chief Scientist’s Office, Ms. Alice Houy, office phone: 210-292-8029; email address: alice.houy.civ@mail.mil.

4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support

*Warrior Medics — Mission Ready — Patient Focused*
INSTRUCTIONS

USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

1. The author must complete page two of this form:
   a. In Section 2, add the funding source for your study (e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants; etc.)
   b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.

2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.

3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.

4. Attach a copy of your abstract, paper, poster and other supporting documentation.

5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.

6. On page 2, have either your unit commander, program director or immediate supervisor:
   a. Print their name, rank/grade, title, sign and date the form in the approving authority's signature block or use an electronic signature.

7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubsres@us.af.mil). If you have any questions or concerns, please contact the 59 CRD/ Publications and Presentations Section at 292-7141 for assistance.

8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.

9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.

10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CICC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DTIC). See 59 MDW 41-168, Presentation and Publication of Medical and Technical Papers, for additional information.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:
"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:
"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AF1 40-402."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401_IP:
"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 85-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."
The Relationship Between Obstructive Sleep Apnea and Hospital Readmission

Assessing how hospital readmissions are affected by obstructive sleep apnea severity and therapy compliance.

10. IS THIS MATERIAL CLASSIFIED? ☑ YES ☐ NO

11. MATERIAL IS FOR: ☑ DOMESTIC RELEASE ☐ FOREIGN RELEASE

CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED.

☐ 11a. PUBLICATION/JOURNAL (List intended publication/journal.)

☐ 11b. PUBLISHED ABSTRACT (List intended journal.)

☒ 11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.)

Sleep 2017, Boston, MA, June 3-7, 2017

☐ 11d. PLATFORM PRESENTATION (At civilian institutions: name of meeting, state, and date of meeting.)

☐ 11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)

12. EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC

NOTE: All publications/presentations are required to be placed in the Defense Technical Information Center (DTIC).

DATE
3/17/2017

13. 59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email)

Scalzitti, Nicholas J; nicholas.j.scalzitti.mil@mail.mil

14. DUTY PHONE/PAGER NUMBER

210-292-6929/210-594-4099

15. AUTHORSHIP AND CO-AUTHOR(S) List in the order they will appear in the manuscript.

LAST NAME, FIRST NAME AND M.I. GRADE/RANK SQUADRON/GROUP/OFFICE SYMBOL INSTITUTION (If not 59 MDW)

a. Primary/Corresponding Author

Scalzitti, Nicholas Capt/O-3 59th TRS/59MDW/SGVT

b. Nielsen, Skyler W Capt/O-3 59 CSPS

c. Dion, Gregory R Maj/O-4 US Army/Otolaryngology Department BAMC

d. Brock, Matthew S Maj/O-4 59MDW/Sleep and Neurology clinics

e. O'Connor, Peter D LtCol/O-5 US Army/Otolaryngology Department BAMC

I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 40-4011, IRB, AND 59 MDW 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.

16. AUTHOR'S PRINTED NAME, RANK, GRADE

Nicholas Scalzitti, Capt, O-3

17. AUTHOR'S SIGNATURE

SCALZITTI, NICHOLAS J 13007497

18. DATE

3/17/2017

19. APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE

Shana Hansen, LtCol, Associate Program Director, Sleep Medicine

20. APPROVING AUTHORITY'S SIGNATURE

HANSEN, SHANA LEE 1232764089

21. DATE

3/20/2017
**PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS**

**1st ENDORSEMENT (59 MDW/SGVU Use Only)**

| TO: Clinical Research Division 59 MDW/CRD  
Contact 292-7141 for email instructions. | 22. DATE RECEIVED | 23. ASSIGNED PROCESSING REQUEST FILE NUMBER |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>March 20, 2017</td>
<td>17156</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>24. DATE REVIEWED</th>
<th>25. DATE FORWARDED TO 502 ISG/JAC</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 21, 2017</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>26. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES:</th>
<th>NO ☐ YES ☐ If yes, give date.</th>
<th>N/A ☐</th>
</tr>
</thead>
</table>

27. COMMENTS ☒ APPROVED ☐ DISAPPROVED

Poster presentation of IRB approved study. Appropriate disclaimers included. Approved

28. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER  
Kevin Kuperer/GS13/Human Research Subject Protection Expert

29. REVIEWER SIGNATURE  
KUPERER KEVIN R 108666727

30. DATE | March 21, 2017

**2nd ENDORSEMENT (502 ISG/JAC Use Only)**

<table>
<thead>
<tr>
<th>31. DATE RECEIVED</th>
<th>32. DATE FORWARDED TO 59 MDW/PA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>33. COMMENTS ☒ APPROVED (In compliance with security and policy review directives.) ☐ DISAPPROVED</th>
</tr>
</thead>
</table>

**3rd ENDORSEMENT (59 MDW/PA Use Only)**

<table>
<thead>
<tr>
<th>37. DATE RECEIVED</th>
<th>38. DATE FORWARDED TO 59 MDW/SGVU</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 21, 2017</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>39. COMMENTS ☒ APPROVED (In compliance with security and policy review directives.) ☐ DISAPPROVED</th>
</tr>
</thead>
</table>

**3rd ENDORSEMENT (59 MDW/PA Use Only)**

<table>
<thead>
<tr>
<th>40. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER</th>
<th>41. REVIEWER SIGNATURE</th>
<th>42. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Inuma, SSgt/E-5, 59 MDW Public Affairs</td>
<td>INUMA KEVIN MITSUGU 1296227</td>
<td>March 21, 2017</td>
</tr>
</tbody>
</table>

**4th ENDORSEMENT (59 MDW/SGVU Use Only)**

<table>
<thead>
<tr>
<th>43. DATE RECEIVED</th>
<th>44. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>YES ☐ NO ☐ COULD NOT BE REACHED ☐ LEFT MESSAGE</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>45. COMMENTS ☒ APPROVED ☐ DISAPPROVED</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>46. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER</th>
<th>47. REVIEWER SIGNATURE</th>
<th>48. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Title: Assessing How Hospital Readmissions are Affected by Obstructive Sleep Apnea Severity and Therapy Compliance

Authors and Institutions: Nicholas Scalzitti, MD1,2; Skyler Nielsen, DO2; Gregory Dion, MD2; Matthew Brock, MD1; Peter O'Connor, MD1,2

1Department of Sleep Medicine, San Antonio Uniformed Services Health Education Consortium, San Antonio, TX; 2Department of Otolaryngology-Head and Neck Surgery, San Antonio Uniformed Services Health Education Consortium, San Antonio, TX

Introduction:

Hospital readmissions are an important quality metric reported to the Centers for Medicare and Medicaid Services. Previous work from our group found that the presence of obstructive sleep apnea (OSA) correlates with increased risk of hospital readmission within 30 days. This project seeks to characterize the relationship between readmissions and the severity and treatment of OSA. A better understanding of this relationship could potentially be utilized to develop preventative measures and reduce readmission.

Methods:

A retrospective review of all hospital discharges over a 24-month period (August 2011–July 2013) for a Department of Defense tertiary care hospital was conducted. Of 22,261 unique discharges, 5,299 patients had OSA based on ICD-9 codes. Of these patients with OSA, 565 were readmitted. From this group, 125 patients were randomly selected for further review. An additional age and gender-matched 125 patients with OSA that were not readmitted were selected for comparison. The groups were compared with parametric and non-parametric tests.

Results:

For the 250 patients, ages ranged from 18 to 96 years (mean 63.2). Polysomnography data was found for 152 patients (77 readmitted and 75 non-readmitted). Based on the available polysomnography data, 67 readmitted and 66 non-readmitted patients met criteria for OSA. Apnea-hypopnea index ranged from 0 to 110.7 (mean 24.1) and 0.2 to 109 (mean 27.2) for the readmitted and non-readmitted groups respectively (p=0.48). Similarly, lowest oxygen saturations averaging 83.9 and 84.1 (p=0.88), and body mass index averaging 31.3 and 31.6 (p=0.67) were not statistically different. Inpatient (27.2% vs. 26.4%) and outpatient (38.4% vs. 37.6%) treatment rates were not different. Length of hospital stay (5.1 vs. 3.6 days in readmitted vs. non-readmitted) differed between the 2 groups (p=0.007).

Conclusion:

While OSA is an independent risk factor for hospital readmission, OSA severity and treatment compliance did not differ between readmitted and non-readmitted patients. Of the factors studied, only
length of stay during the original admission correlated with higher likelihood of readmission. Additional studies on hospital readmission in OSA patients are needed to determine if readmission rates can be improved through better recognition and treatment of OSA.

Disclaimer:

The views expressed are those of the author(s)/presenter(s) and do not reflect the official views or policy of the Department of Defense or its Components.